Tag
This review synthesizes current evidence on pulse versus nonpulse corticosteroid therapy in AE-IPF, contextualizing the SAFER trial findings within prior studies and clinical guidelines to guide management and future research.
Emerging evidence reveals gut microbiota profiles correlate with disease severity and survival in idiopathic pulmonary fibrosis, highlighting potential microbial biomarkers and treatment modifiers.
Age-adjusted WGS-estimated telomere length improves identification of pathologically short telomeres and detection of telomere-related variants in IPF, associating with survival outcomes but offering limited survival prediction beyond clini
This study investigates how dose reductions and discontinuations of antifibrotic therapies influence disease progression in idiopathic pulmonary fibrosis (IPF), revealing significant challenges in drug tolerability and the need for improved
A polygenic risk score (PRS) significantly associates with IPF diagnosis and mortality, demonstrating potential for improving clinical risk stratification using real-world biobank data.
Combined analysis of the TETON-1 and TETON-2 trials confirms inhaled treprostinil significantly slows lung function decline, reduces clinical worsening and exacerbations, and improves quality of life in idiopathic pulmonary fibrosis over on
A randomized, double-blind, placebo-controlled trial demonstrates gabapentin’s significant efficacy and acceptable safety for treating cough in IPF, supporting its clinical use amid limited alternatives.
Deupirfenidone, a deuterated form of pirfenidone, demonstrated efficacy in slowing lung function decline in IPF patients, with a favorable safety profile in a phase 2b trial, offering promise for improved treatment outcomes.
Genetic risk loci for idiopathic pulmonary fibrosis (IPF) identified in East Asian populations largely overlap with those found in Europeans, though allele frequencies and effect sizes differ, highlighting shared ancestry and disease mechan
A multicenter study suggests that 1-year quantitative CT fibrosis progression in IPF, particularly a rise of about 4%, is clinically meaningful and prognostically informative for transplant-free survival.
An in-depth analysis of the FIBRONEER-IPF trial’s extended follow-up data, evaluating the efficacy and safety of the PDE4B inhibitor nerandomilast in reducing clinical events and mortality in patients with idiopathic pulmonary fibrosi
Long-term data from the FIBRONEER-IPF trial indicates that while nerandomilast did not significantly impact composite respiratory events, the 18 mg dose suggests a numerical reduction in mortality and maintains a favorable safety profile fo
This article analyzes the long-term follow-up data from the FIBRONEER-IPF trial, evaluating the efficacy of nerandomilast in idiopathic pulmonary fibrosis. While the drug reduces FVC decline, its impact on composite clinical outcomes remain
A landmark study identifies a decade-long conserved sequence of disease progression in IPF, revealing that DLCO decline precedes FVC impairment by years, providing a new framework for early diagnosis and clinical trial design.
The CORAL Phase 2b trial demonstrates that oral nalbuphine extended release significantly reduces objective cough frequency and improves patient-reported symptoms in idiopathic pulmonary fibrosis, addressing a critical unmet need for managi
The Phase 2a ENV-IPF-101 trial demonstrates that taladegib, a Hedgehog pathway inhibitor, not only stabilizes but may improve forced vital capacity and reduce fibrotic burden in patients with idiopathic pulmonary fibrosis over 12 weeks.
This phase 2 trial demonstrates that bexotegrast, a dual αvβ6/αvβ1 integrin inhibitor, significantly reduces active type I collagen deposition in IPF lungs, indicating antifibrotic potential and favorable lung remodeling over 12 weeks.
The INTEGRIS-IPF trial demonstrates that bexotegrast is well tolerated and may reduce lung function decline in IPF patients, offering hope for a novel antifibrotic therapy.
Rentosertib, an AI-designed TNIK inhibitor, demonstrated safety and preliminary efficacy in idiopathic pulmonary fibrosis in a randomized phase 2a trial, marking a milestone in AI-driven drug development for progressive lung diseases.
Phase 3 trials demonstrate that nerandomilast, a selective PDE4B inhibitor, significantly slows lung function decline in idiopathic and progressive pulmonary fibrosis over 52 weeks, with manageable safety profiles.
